If you are an adult between 19 and 59 and were never vaccinated against hepatitis B, the answer is straightforward: you should get vaccinated now. The CDC’s Advisory Committee on Immunization Practices expanded its recommendation in April 2022 to include all adults in that age range, regardless of whether you have specific risk factors. That was a significant shift from earlier guidance, which targeted only people in high-risk categories. For hepatitis A, the recommendation remains risk-based, but a combination vaccine called Twinrix lets you cover both diseases in a single series — a practical option if you fall into overlapping risk groups or simply want broader protection.
Consider someone in their mid-40s who never received childhood hepatitis B shots — which were not universally recommended for infants until 1991 — and who is now planning travel to Southeast Asia, where hepatitis A is endemic. That person would benefit from the combo vaccine rather than juggling two separate shot series. Adults aged 40 to 59 account for a disproportionate share of acute hepatitis B cases, making catch-up vaccination in this group especially important. This article walks through who specifically needs to catch up, how the combo vaccine compares to single-antigen options, what the standard and accelerated dosing schedules look like, what it costs with and without insurance, and what recent policy changes from late 2025 mean for adults seeking vaccination.
Table of Contents
- Who Needs to Catch Up on the Hepatitis A and B Combo Vaccine as an Adult?
- Understanding What Twinrix Contains and How It Differs from Standalone Vaccines
- Why Adult Vaccination Coverage Remains Stubbornly Low
- Comparing Your Hepatitis B Vaccine Options as an Adult
- What Twinrix Costs and How Insurance Changes in 2026 Affect Coverage
- What the December 2025 ACIP Changes Mean for Adults
- The Road Ahead for Hepatitis Elimination
- Conclusion
- Frequently Asked Questions
Who Needs to Catch Up on the Hepatitis A and B Combo Vaccine as an Adult?
The simplest way to think about it is in two tiers. For hepatitis B, every adult aged 19 through 59 should receive the vaccine — full stop. You do not need a documented risk factor. You do not need to be a healthcare worker or have a history of injection drug use. The ACIP’s 2022 universal recommendation closed the gap that had left millions of adults unprotected simply because they did not fit neatly into a risk category. If you are 60 or older, the calculus is slightly different: vaccination is recommended if you have risk factors such as chronic liver disease, HIV infection, occupational exposure, sexual exposure risk, or injection drug use. If you are over 60 without those risk factors, you can still receive the vaccine if you want the protection, but it is not a blanket recommendation.
Hepatitis A vaccination for adults remains risk-based rather than universal. The CDC recommends it for unvaccinated adults who face increased risk of infection or severe outcomes. That includes international travelers to countries with high or intermediate hepatitis A endemicity, men who have sex with men, people who use or inject drugs, those with chronic liver disease, and people experiencing homelessness. If you check a box in both the hepatitis B universal category and the hepatitis A risk-based category — say, a 35-year-old planning extended travel abroad — the Twinrix combo vaccine is an efficient way to address both. One comparison worth noting: a 45-year-old office worker with no particular risk factors still qualifies for hepatitis B vaccination under the universal recommendation but would not be a candidate for hepatitis A vaccination unless a risk factor applies. In that case, a single-antigen hepatitis B vaccine would be more appropriate than Twinrix. The combo vaccine is not a default for everyone; it makes the most sense when both components are indicated.
Understanding What Twinrix Contains and How It Differs from Standalone Vaccines
Twinrix, manufactured by GSK, is the only FDA-licensed combination hepatitis A and B vaccine approved for adults aged 18 and older. Each dose contains 720 EL.U. of hepatitis A antigen — which is half the amount found in a standalone adult dose of Havrix — and 20 micrograms of hepatitis B antigen, which matches the full adult dose of Engerix-B. The lower hepatitis A antigen content per dose is compensated by the fact that you receive three doses over the course of the series. The standard Twinrix schedule calls for three doses administered at 0, 1, and 6 months.
The minimum interval between the first and second dose is four weeks, and between the second and third dose is five months. This mirrors the timing of the three-dose Engerix-B series, so if you are already planning a hepatitis B series on that timeline, adding hepatitis A protection does not require additional visits. However, if you need rapid protection — for instance, you have a trip departing in three weeks — the standard schedule will not get you there in time. Twinrix does offer an accelerated four-dose schedule: doses at day 0, day 7, day 21 to 30, and a booster at 12 months. This can provide earlier immune response for both diseases, though the 12-month booster is still necessary for long-term protection. The tradeoff is an extra dose and an extra clinic visit compared to the standard series, and you will need to remember that fourth shot a year later even if the urgent reason for vaccination has passed.
Why Adult Vaccination Coverage Remains Stubbornly Low
Despite clear recommendations, adult hepatitis B and A vaccination rates remain disappointing. In 2023, there were 2,214 reported acute hepatitis B cases in the United States, but the CDC estimates the true number of acute infections was approximately 14,400 after adjusting for underreporting and underdiagnosis. The reported rate stood at 0.7 per 100,000 population, with adults aged 40 to 59 accounting for 48 percent of all reported acute cases. These are largely vaccine-preventable infections occurring in an age group that grew up before universal infant hepatitis B vaccination was in place. Hepatitis A tells a somewhat more encouraging story, at least in terms of trajectory. An estimated 3,300 new hepatitis A infections occurred in 2023, representing a 51 percent reduction from the 2017 baseline.
That decline followed a dramatic surge that peaked in 2019, driven by outbreaks among people who use drugs and people experiencing homelessness. Community-level vaccination campaigns in affected populations helped bend the curve, but coverage among high-risk adults remains inadequate. The gap between recommendation and reality is partly structural. Many adults do not have a regular primary care provider prompting them on immunizations. Pharmacies have helped close this gap, but awareness remains low. A 50-year-old who sees a doctor for a knee problem is unlikely to hear about hepatitis B catch-up vaccination during that visit unless the practice has strong preventive care protocols. The result is that the people most at risk — middle-aged adults who missed childhood vaccination — are often the least likely to be offered the vaccine proactively.
Comparing Your Hepatitis B Vaccine Options as an Adult
If you only need hepatitis B protection, you have several choices beyond Twinrix. The two traditional single-antigen options are Engerix-B and Recombivax HB, both requiring three doses. Then there is Heplisav-B, which requires only two doses given at least four weeks apart — a genuine advantage for adults who struggle with multi-visit adherence. Fewer appointments means fewer chances to fall off the schedule. One option that is no longer available is PreHevbrio, a three-antigen hepatitis B vaccine that was voluntarily withdrawn from the U.S. market in October 2024 due to the manufacturer’s bankruptcy. The withdrawal was not related to safety concerns.
If you started a series with PreHevbrio before it was pulled, the CDC confirms you can complete your series with any other licensed hepatitis B vaccine. You do not need to start over. The tradeoff between Twinrix and Heplisav-B is worth weighing carefully. Heplisav-B gets you full hepatitis B protection in just two visits over one month. Twinrix requires three visits over six months but adds hepatitis A coverage. If hepatitis A vaccination is indicated for you, Twinrix saves you from needing a separate Havrix series. If it is not, Heplisav-B is the faster, simpler path to hepatitis B immunity. Your provider can help sort out which makes sense based on your risk profile and travel plans.
What Twinrix Costs and How Insurance Changes in 2026 Affect Coverage
Cost can be a real barrier, particularly for the uninsured. Twinrix runs approximately $135 to $217 per dose at retail pricing, which translates to roughly $400 to $500 for a full three-dose series out of pocket. The accelerated four-dose schedule would cost even more. For comparison, Heplisav-B’s two-dose series may be more economical if you only need hepatitis B protection, though pricing varies by pharmacy and region. Most private insurance plans cover hepatitis B vaccination at no out-of-pocket cost under the Affordable Care Act’s preventive services mandate, since it carries an ACIP recommendation. Hepatitis A coverage through private insurance can be less consistent and may depend on whether your provider documents a qualifying risk factor.
For Medicare beneficiaries, a meaningful change takes effect in 2026: all CDC-recommended adult vaccines, including hepatitis A, will be covered under Medicare Part D with zero cost-sharing. Previously, hepatitis A vaccination under Medicare Part D could carry copays of around $34 per dose, which added up across a multi-dose series. One limitation to be aware of: even with insurance, coverage does not guarantee access. Some pharmacies may not stock Twinrix and will only carry single-antigen vaccines. Rural areas may have fewer options. And if you are on the accelerated schedule, getting that 12-month booster covered can occasionally trigger confusion with insurance billing systems that flag an apparent “extra” dose. Keep your vaccination card and have your provider document the accelerated schedule clearly.
What the December 2025 ACIP Changes Mean for Adults
In December 2025, ACIP voted to shift the infant hepatitis B birth dose to an individual-based decision-making model for babies born to mothers who test negative for hepatitis B surface antigen. This generated headlines and some confusion, but it is important to understand that this change applies exclusively to newborns. The universal adult recommendation for ages 19 to 59 remains fully intact and was not part of the December discussion.
Separately, the 2025 Adult Immunization Schedule introduced clarifications in the hepatitis B notes section and removed Heplisav-B from the column of vaccines not recommended during pregnancy, since the pregnancy registry monitoring that product is no longer active. For most adults seeking catch-up vaccination, these changes are administrative rather than substantive. The core guidance — get vaccinated if you are under 60, consider it strongly if you are over 60 with risk factors — has not shifted.
The Road Ahead for Hepatitis Elimination
The broader context for all of this is the federal goal of eliminating viral hepatitis as a public health threat in the United States. The 51 percent reduction in hepatitis A infections from 2017 to 2023 shows that vaccination campaigns can move the needle when resources are directed at affected communities. Hepatitis B is proving more stubborn, in part because the reservoir of chronically infected adults — many of whom were infected at birth or in early childhood before vaccines were available — continues to drive transmission even as new acute cases slowly decline.
Closing the adult vaccination gap is one of the more actionable levers available. Every unvaccinated 45-year-old who receives a catch-up series is one fewer potential acute case and one fewer link in a transmission chain. With Medicare removing cost barriers in 2026 and pharmacies increasingly authorized to administer vaccines without a physician visit, the infrastructure is improving. The remaining challenge is awareness — making sure adults know that this recommendation applies to them, not just to infants and teenagers.
Conclusion
The bottom line is that most adults under 60 should receive hepatitis B vaccination if they have not already, and adults with specific risk factors should add hepatitis A to the list. Twinrix offers a practical way to cover both in one series, particularly for travelers, people with chronic liver disease, and others who meet criteria for both vaccines. For those who only need hepatitis B, Heplisav-B’s two-dose schedule is the most streamlined option currently available.
Talk to your pharmacist or primary care provider about your vaccination history. If you are unsure whether you were vaccinated as a child, a simple blood test can check for existing antibodies. With insurance increasingly covering these vaccines at no cost — and Medicare eliminating copays starting in 2026 — the financial barriers are lower than they have ever been. There is little reason to leave yourself unprotected against two diseases that are entirely preventable.
Frequently Asked Questions
Can I get Twinrix if I already completed a hepatitis B series but never had hepatitis A vaccination?
Generally, no — Twinrix is not recommended if you have already completed a hepatitis B series, because you would be receiving unnecessary additional hepatitis B antigen. In that case, a standalone hepatitis A vaccine like Havrix would be more appropriate. Discuss with your provider if your situation is unclear.
What if I started the Twinrix series but missed the third dose by several months?
You do not need to restart the series. The third dose can be administered late, and the earlier doses still count. The key principle with vaccine scheduling is that doses given after the minimum interval remain valid; you pick up where you left off rather than starting over.
Is Twinrix safe for people with weakened immune systems?
Twinrix is not a live vaccine, so it is generally considered safe for immunocompromised individuals. However, the immune response may be reduced, meaning you might not develop full protection. Your provider may recommend checking antibody levels after the series to confirm adequate immunity.
I started my series with PreHevbrio before it was withdrawn. What do I do now?
You can complete your hepatitis B series with any other licensed vaccine, including Engerix-B, Recombivax HB, or Heplisav-B. The CDC has confirmed that mixing products is acceptable when one becomes unavailable. You do not need to start the series from the beginning.
Does the accelerated Twinrix schedule provide the same long-term protection as the standard schedule?
Yes, provided you complete all four doses, including the 12-month booster. The accelerated schedule offers earlier initial protection, but the booster at 12 months is essential for durable, long-term immunity. Skipping that final dose may leave you with inadequate long-term protection.
Should adults over 60 bother getting hepatitis B vaccination if they have no risk factors?
It is not a strong recommendation in that group, but it is permitted. The ACIP guidance says adults 60 and older without risk factors may receive the vaccine if they desire protection. If you have any uncertainty about your risk level — or simply want the peace of mind — vaccination is a reasonable choice, especially as cost barriers continue to decrease.
